New Market Study Published: Turkey Pharmaceuticals & Healthcare Report Q1 2014
Despite a challenging pricing and reimbursement situation, BMI still believes the market is attractive in the long term as higher y-o-y growth rates return from 2013/14. In contrast to European markets where manufacturers can expect to achieve higher prices, but with a stagnant growth outlook, Turkey offers strong growth potential if drugmakers are able to accept a price that is considerably below the European average and turn a profit on the low margins available.
View full press release